M&A / Deals Sidewinder pockets $137m in Series B to take bispecific ADCs to clinic Pharmaceutical TechnologyThe funding round, led by Novartis and OrbiMed, will allow Sidewinder to progress its bispecific ADC programmes to the clinic.M&A / DealsOncologyRead full story pharminent April 8, 2026 (Last updated: April 8, 2026) Pharmaceutical Technology The funding round, led by Novartis and OrbiMed, will allow Sidewinder to progress its bispecific ADC programmes to the clinic. M&A / DealsOncologyRead full story Post navigation Previous: Activist investor renews its criticism of NovavaxNext: Medicare Advantage Insurers Will See Higher Payments as CMS Backs Off a Key Payment Update Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026